GLP-1 medicines, NAD+ preparations, and sermorelin are different treatment categories. Their names may appear together on a wellness platform, but that does not make them interchangeable or establish that combining them improves weight outcomes.
Evaluate each proposed therapy separately. Ask what clinical need it addresses, what direct evidence supports that use, and how the clinician will assess benefit and risk.
Do not transfer evidence between therapies
An approved obesity medicine’s trial does not establish the effectiveness of an NAD+ injection or sermorelin preparation. A general discussion of metabolism or growth-hormone signaling is not a clinical outcome study of the actual product.
A person considering a wellness therapy should ask whether the evidence matches the ingredients, route, population, and goal.
Identify the actual prescription
CoreAge’s public pages list separate NAD+ injectable and sermorelin offers, with separate prices. Those should not be folded into its semaglutide or tirzepatide bill without an explicit order.
The NAD+ guide and sermorelin comparison explain what is publicly advertised and which questions remain.
Consider the complete clinical plan
Discuss all current and proposed medicines with the prescriber. More ingredients or more therapies do not automatically produce a better outcome. Each should have a clear rationale, directions, follow-up, and cost.
The CoreAge review connects its public offer pages while keeping their distinct purposes and evidence boundaries visible.
Continue your comparison
Compare the GLP-1 programs, read the CoreAge Rx review, and use the program table to prepare questions about the complete offer.
Sources & offer details
Public information retrieved on October 1, 2026. Provider statements describe the advertised offer; they do not independently establish treatment outcomes.